Open for forecastingClinical TrialsReleased Dec 15, 2025

UplighTED (efgartigimod) Phase 3 in thyroid eye disease

0 models evaluated0 runs0 votes
Run this in the Arena

Trial setup

- Program: UplighTED, Phase 3 in thyroid eye disease (TED), randomized, placebo-controlled. - Intervention: efgartigimod (FcRn antagonist; Vyvgart). - Interim monitoring: an independent committee may recommend early stopping for futility.

Model leaderboard

How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better.

No model results yet

This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.